Renal cell carcinoma with clear cell and papillary features

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 4, 2012, Pages 391-399

  Ross, Hillary ^a   Martignoni, Guido ^b   Argani, Pedram ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE TRANSLOCATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; PAPILLARY CARCINOMA; PATHOLOGY;

CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CYTOGENETICS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84860005570     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0479-RA     Document Type: Article

References (54)

1. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26(3):281-291. (Pubitemid 34184451)
2. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27(5):612-624. (Pubitemid 36514472)
3. Ficarra V, Martignoni G, Galfano A, et al. Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. Eur Urol. 2006;50(4):786- 793; discussion 793-794.
4. Reuter VE, Tickoo SK. Adult renal tumors. In: Mills SE, ed. Sternberg's Diagnostic Surgical Pathology. Vol 2. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:1757-1798.
5. Choudhary S, Sudarshan S, Choyke PL, Prasad SR. Renal cell carcinoma: recent advances in genetics and imaging. Semin Ultrasound CT MR. 2009;30(4):315-325.
6. Ficarra V, Brunelli M, Cheng L, et al. Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol. 2010;58(5):655-668.
7. Minardi D, Lucarini G, Filosa A, et al. Do DNA-methylation and histone acetylation play a role in clear cell renal carcinoma?: analysis of radical nephrectomy specimens in a long-term follow-up. Int J Immunopathol Pharmacol. 2011;24(1):149-158.
8. Rohan SM, Xiao Y, Liang Y, et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel- Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol. 2011;24(9):1207-1220.
9. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85-90. (Pubitemid 24232386)
10. Kovacs G, Erlandsson R, Boldog F, et al. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci U S A. 1988;85(5):1571-1575. (Pubitemid 18070801)
11. van den Berg A, Buys CH. Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes Cancer. 1997;19(2):59-76. (Pubitemid 27231480)
12. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14(15):4726-4734.
13. Fuzesi L, Gunawan B, Bergmann F, Tack S, Braun S, Jakse G. Papillary renal cell carcinoma with clear cell cytomorphology and chromosomal loss of 3p. Histopathology. 1999;35(2):157-161. (Pubitemid 29378516)
14. Salama ME, Worsham MJ, DePeralta-Venturina M. Malignant papillary renal tumors with extensive clear cell change: a molecular analysis by microsatellite analysis and fluorescence in situ hybridization. Arch Pathol Lab Med. 2003;127(9):1176-1181. (Pubitemid 37093267)
15. Jones TD, Eble JN, Wang M, et al. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res. 2005;11(20):7226-7233. (Pubitemid 41507679)
16. Pedrosa I, Alsop DC, Rofsky NM. Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer. 2009;115(10)(suppl):2334-2345.
17. Yoshimitsu K, Irie H, Tajima T, et al. MR imaging of renal cell carcinoma: its role in determining cell type. Radiat Med. 2004;22(6):371-376. (Pubitemid 40144012)
18. Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30(2):141-153. (Pubitemid 43740182)
19. Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol. 2010;34(11):1608-1621.
20. Michal M, Hes O, Havlicek F. Benign renal angiomyoadenomatous tumor: a previously unreported renal tumor. Ann Diagn Pathol. 2000;4(5):311-315.
21. Michal M, Hes O, Kuroda N, Kazakov DV, Hora M. Difference between RAT and clear cell papillary renal cell carcinoma/clear renal cell carcinoma. Virchows Arch. 2009;454(6):719.
22. Michal M, Hes O, Nemcova J, et al. Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity. Virchows Arch. 2009;454(1):89-99.
23. Behdad A, Monzon F, Hes O, et al. Relationship between sporadic clear cell-papillary renal cell carcinoma (CP-RCC) and renal angiomyoadenomatous tumor (RAT) of the kidney: analysis by virtual-karyotyping, fluorescent in situ analysis and immunohistochemistry (IHC). Mod Pathol. 2011;24(suppl 1):179A.
24. Kuhn E, De Anda J, Manoni S, Netto G, Rosai J. Renal cell carcinoma associated with prominent angioleiomyoma-like proliferation: report of 5 cases and review of the literature. Am J Surg Pathol. 2006;30(11):1372-1381. (Pubitemid 44655470)
25. Shannon BA, Cohen RJ, Segal A, Baker EG, Murch AR. Clear cell renal cell carcinoma with smooth muscle stroma. Hum Pathol. 2009;40(3):425-429.
26. Brunelli M, Menestrina F, Segala D, et al. Renal cell carcinoma associated with prominent leiomyomatous proliferation appears not to be a variant of clear cell renal cell carcinoma. Mod Pathol. 2009;22(suppl 1):160A-161A.
27. Kuroda N, Tamura M, Tanaka Y, et al. Adult-onset renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusion with smooth muscle stroma and abnormal vessels. Pathol Int. 2009;59(7):486-491.
28. Reuter VE, Tickoo SK. Differential diagnosis of renal tumours with clear cell histology. Pathology. 2010;42(4):374-383.
29. Gobbo S, Eble JN, Grignon DJ, et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol. 2008;32(8):1239-1245.
30. Kuroda N, Michal M, Hes O, et al. Renal angiomyoadenomatous tumor: fluorescence in situ hybridization. Pathol Int. 2009;59(9):689-691.
31. Adam J, Couturier J, Molinie V, Vieillefond A, Sibony M. Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases. Histopathology. 2011;58(7):1064-1071.
32. Dijkhuizen T, van den Berg E, Wilbrink M, et al. Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X;autosome translocations. Genes Chromosomes Cancer. 1995;14(1):43-50.
33. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31(8):1149-1160. (Pubitemid 47207116)
34. Argani P, Lui MY, Couturier J, Bouvier R, Fournet J, Ladanyi M. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2; q23). Oncogene. 2003;22(34):5374-5378. (Pubitemid 37056101)
35. Clark J, Lu YJ, Sidhar SK, et al. Fusion of splicing factor genes PSF and NonO(p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene. 1997;15(18):2233-2239. (Pubitemid 27493913)
36. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159(1):179-192. (Pubitemid 33704203)
37. Argani P, Antonescu CR, Couturier J, et al. PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol. 2002;26(12): 1553-1566. (Pubitemid 35387219)
38. Argani P, Laé M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006;24(10):1529-1534. (Pubitemid 46638774)
39. Rais-Bahrami S, Drabick JJ, De Marzo AM, et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapyassociated secondary malignancy. Urology. 2007;70(1):178.e3-178.e6.
40. Komai Y, Fujiwara M, Fujii Y, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009;15(4):1170-1176.
41. Zhong M, Osborne L, Merino MJ, Hameed M, Aisner S. The study of Xp11 translocation renal cell carcinoma (RCC) in adults by TMA, IHC and FISH [abstract]. Mod Pathol. 2010;23(suppl 1):232A.
42. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology. 2010;42(4):369-373.
43. Meyer PN, Clark JI, Flanigan RC, Picken MM. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol. 2007; 128(1):70-79. (Pubitemid 47121717)
44. Geller JI, Argani P, Adeniran A, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008;112(7):1607-1616. (Pubitemid 351441175)
45. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34(9):1295-1303.
46. Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009;22(8):1016-1022.
47. MartignoniG, Gobbo S, Camparo P, et al.Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod Pathol. 2011;24:1313-1319.
48. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6):750-761. (Pubitemid 36617511)
49. Aulmann S, Longerich T, Schirmacher P, Mechtersheimer G, Penzel R. Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas. Histopathology. 2007;50(7):881-886. (Pubitemid 46850067)
50. Zhong M, De Angelo P, Osborne L, et al. Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol. 2010;34(6):757-766.
51. Green WM, Netto GJ, Griffin CA, Morsberger LA, Illei PB, Xhou X, Argani P. Utilization of a TFE3 break-apart fluorescence in situ hybridization assay in a renal tumor consultation service. Poster to be presented at: United States & Canadian Academy of Pathology Annual Meeting; March 17-23, 2012; Vancouver, BC, Canada.
52. Al-Ahmadie HA, Alden D, Fine SW, et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol. 2011;35(7):949-961.
53. Gobbo S, Eble JN, Maclennan GT, et al. Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis. Am J Surg Pathol. 2008;32(12):1780-1786.
54. Mai KT, Faraji H, Desantis D, Robertson SJ, Belanger EC, Levac J. Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study. Virchows Arch. 2010;456(1):77-84.